1 Bacterial culture use, etiology and antibiotic susceptibility of common bacterial

2 infections in Indonesian hospitals in 2019

3 Authors

- 4 Justin de Brabander^{1,2}, Erni J. Nelwan^{3,4,5,6}, Ralalicia Limato^{1,7}, Monik Alamanda¹, Manzilina
- 5 Mudia¹, Enty Tjoa^{8,9}, Ifael Y. Mauleti¹⁰, Maria Mayasari¹¹, Iman Firmansyah¹², T. Mannaria
- ⁶ Jayati⁶, Michèle van Vugt², H. Rogier van Doorn^{7,13}, Raph L. Hamers^{1,3,7}

7 Affiliations

- 8 1. Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia
- 9 2. Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC,
- 10 University of Amsterdam, Amsterdam, The Netherlands
- 11 3. Faculty of Medicine, University of Indonesia, Jakarta, Indonesia
- 12 4. Department of Internal Medicine, Division of Infectious Diseases, Cipto Mangunkusumo
- 13 National General Hospital, Jakarta, Indonesia
- 14 5. Infectious Disease and Immunology Research Cluster, Indonesian Medical Education and
- 15 Research Institute, Jakarta, Indonesia
- 16 6. Metropolitan Medical Centre Hospital, Jakarta, Indonesia
- 17 7. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University
- 18 of Oxford, Oxford, UK
- 19 8. Royal Taruma Hospital, Jakarta, Indonesia
- 20 9. School of Medicine and Health Sciences, Atma Jaya Catholic University, Jakarta, Indonesia
- 21 10. Fatmawati General Hospital, Jakarta, Indonesia
- 22 11. St. Carolus Hospital, Jakarta, Indonesia
- 23 12. Prof. Dr. Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia
- 24 13. Oxford University Clinical Research Unit, Hanoi, Vietnam

25

- 26 *Corresponding author
- 27 Raph L. Hamers MD PhD
- 28 Email : raph.hamers@ndm.ox.ac.uk
- 29 Phone : +62 21 31900971
- 30 Fax :-
- 31
- 32 **Running title:** Antibiotic resistance in Indonesian hospitals
- 33 Word count: 1499
- 34 **Inserts:** 2 figures
- 35 Supplementary data: 4 tables; 3 figures

36 Abstract

37

38 **Objectives:** To describe the use of bacterial cultures, and the etiology and antibiotic

39 susceptibility of common high-priority bacteria isolated from hospitalized patients in Jakarta,

40 Indonesia.

41 **Methods:** We conducted a hospital-wide cross-sectional study of all inpatients receiving

42 systemic antibiotic treatment (WHO ATC J01) in six hospitals in 2019, capturing routine data on

43 antibiotic treatment and cultures. We reported bug-drug combinations for *Escherichia coli* and

44 the ESKAPE group of bacteria.

45 **Results:** 562 patients (52% women, median age 46 years) had 587 diagnoses, with pneumonia

46 (258, 44%) most common. One or more culture specimens were taken in 38% (215/562) overall,

47 a sputum culture in 25% (64/258) of pneumonia patients; and a blood culture in 52% (16/31) of

48 sepsis patients. 50% of positive blood culture results were reported after ≥4 days. From 670

49 culture specimens, 279 bacteria were isolated, 214 (77%) were Gram-negative, including

50 Klebsiella pneumoniae (70, 25%), Pseudomonas aeruginosa (36, 13%), and E. coli (21, 11%).

51 Resistance included third-generation cephalosporin-resistant *K. pneumoniae* (77%), *E. coli*

52 (65%) and Enterobacter spp (81%); carbapenem-resistant K. pneumoniae (26%), P. aeruginosa

53 (24%), E. coli (33%), Acinetobacter spp (57%), and Enterobacter spp (60%); and meticillin-

resistant S. aureus (71%). Vancomycin-resistant S. aureus (0%) and Enterococcus faecalis

55 (12%) were uncommon. Multi-drug resistance was 30% for *K. pneumoniae*, 29% for *P.*

56 aeruginosa, 49% for *E. coli*, 42% for *Acinetobacter spp*, and 71% for *S. aureus*.

57 **Conclusions:** In Indonesian hospitals, bacterial cultures were underused and antibiotic

resistance is at alarming levels. Enhanced context-specific infection prevention, diagnostic and

59 antibiotic stewardship interventions are urgently needed.

60 Introduction

61

0.	-
62	2 Antibiotic-resistant bacterial infections caused an estimated 1.27 million deaths in 2019, with
63	worst impacts in low- and middle-income countries (LMICs). ¹ The consumption of antimicrobial
64	agents is one of the key drivers of antimicrobial resistance (AMR). ^{2,3} Continuous epidemiological
65	5 surveillance of AMR patterns in each country and hospital is warranted to establish evidence-
66	based policies. Southeast Asia has been identified of great importance in the emergence and
67	7 spread of AMR. ^{4,5} Indonesia, a diverse lower-middle-income country with the world's fourth
68	³ largest populace (275 million), is particularly vulnerable to AMR ⁶ , because of rapidly increasing
69	antibiotic consumption ⁷ and weakly enforced antibiotic policies. ⁸ Systemic data are lacking to
7(estimate the extent of AMR in hospitals. ⁹⁻¹¹
7:	1
72	2 This study aimed to describe the use of bacterial cultures, and the etiology and antibiotic
73	3 susceptibility of common high-priority bacterial infections in hospitalized patients in Jakarta,
74	4 Indonesia.
75	
76	5 Materials and methods
7	7
78	3 Study design and setting
79	We conducted a hospital-wide cross-sectional survey in a purposively varied sample of six
8(hospitals (3 private and 3 public; 4 secondary and 2 tertiary) in Jakarta between March and
83	August 2019, as previously described. ¹² The present analysis included all inpatients who started
82	2 systemic antibiotic treatment (ATC J01) for a presumed bacterial infection, and we extracted
83	data from medical and laboratory records. Antibiotic indications were classified as community
84	acquired infection (CAI) (symptoms present on admission or started <48 hours after admission),
85	or hospital acquired infection (HAI) (symptoms started >48 hours after admission at the study

- site). The study was approved by the Research Ethics Committee of the Faculty of Medicine of
- the University of Indonesia and the Oxford Tropical Research Ethics Committee; the
- requirement for individual patient consent was waived.
- 89

90 <u>Microbiological diagnostic testing</u>

91 All culture specimens taken as part of routine clinical care during their current admission

92 (including <7 days prior) were included. Non-susceptibility was defined as intermediate or

- resistant, based on CSLI and/or EUCAST breakpoints. The analysis focused on the most
- 94 relevant bacteria for hospital settings, Enterococcus species, Staphylococcus aureus, Klebsiella

95 pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species,

96 (i.e. ESKAPE group), and Escherichia coli, and common bacteria-antibiotic combinations

97 (including those in the WHO priority pathogen list¹³). Multi-drug resistance was defined as non-

susceptibility to at least one agent in three or more antimicrobial categories, based on the 2011

99 ECDC definition.¹⁴ Where susceptibility results were given for more than one antibiotic of a

same class (e.g. fluoroquinolones, carbapenems), the highest resistance proportion was

selected to represent the proportion for that respective class.

102

103 Statistical analysis

Data are presented as counts (percentage of total), mean (±SD) or median [IQR]. Differences between subgroups were analyzed using the Pearson's chi-squared test, unpaired t-test or Mann-Whitney U test, whichever appropriate. P-values of <0.05 were considered statistically significant. All statistical analyses were performed using R version 4.1.0.

108

109 Results

110

111 Patient characteristics

112	Among 1602 hospitalized patients, 562 (35.1%) received one or more antibiotics for the
113	treatment of a presumed bacterial infection (Figure S1). This comprised 777 prescriptions for
114	587 distinct diagnoses, the most common being pneumonia (44.0%, 258), followed by skin and
115	soft tissue (SST) (12.6%, 74), gastrointestinal (10.9%, 64), urinary tract (UTI) (7.7%, 45) and
116	intra-abdominal infections (5.5%, 32), and sepsis (5.3%, 31). This included 69.8% (542) CAIs
117	and 30.2% (235) HAIs. The median age was 46 years (IQR 20-60), and 52% were women.
118	33.8% (190) of patients had been hospitalized in the three months before their current
119	admission, and 23.8% (134) had undergone surgery in the previous three months. On average,
120	patients who had one or more bacterial cultures taken, compared to those who had not, were
121	younger, had lower body weight, and were more likely to have national health insurance, one or
122	more catheters and a history of recent surgery or hospitalization (Table S1).
123	
124	Use and reporting of bacterial cultures
125	Proportions of patients in whom one or more bacterial cultures were performed were 38.3%
126	(215/562) overall; 39.9% (103/258) of pneumonia patients (sputum 24.8% [64] and blood 20.5%
127	[53]); 44.6% (33/74) of skin and soft tissue (SST) infection patients (wound 25.7% [19], blood
128	14.9% [11], pus 13.5% [10]); 51.1% of urinary tract infection (UTI) patients (urine 44.4% [20]
129	and blood 33.3% [15]); and 54.8% (17/31) of sepsis patients (blood 51.6% [16]) (Figure S2).
130	The median time from culture specimen collection to reporting positive results (etiology and
131	antibiotic-susceptibility) was 4 (3-4) days for blood, 3 (2-4) days for sputum and 3 (2-3) days for
132	urine (Figure S3).
133	
134	Bacterial etiology of infectious syndromes
135	Overall, 279 bacteria were isolated from 670 culture specimens, including 100 bacterial isolates
136	from 239 culture specimens in CAI and 179 isolates from 431 culture specimens in HAI (Figure

137 **1**). The proportion of positive blood cultures was 14.8% (39/263). Overall, 76.7% (214/279) of

isolates were Gram-negative bacteria. Most common bacteria were K. pneumoniae (25.1%, 70),

- 139 P. aeruginosa (12.9%, 36), E. coli, coagulase-negative staphylococci (each 11.8%, 33),
- Acinetobacter spp (10.8%, 30) and Enterobacter spp (9.0%, 25) (**Table S2**). Enterococcus
- 141 *faecium* was not isolated.

142

- 143 **Table S2** summarizes etiologies of CAIs and HAIs. In both community-acquired and hospital-
- acquired pneumonia, the most frequent isolates were K. pneumoniae (26.5% [9/34] and 36.8%
- 145 [25/68], respectively), Acinetobacter spp (26.5% [9/34] and 19.1% [13/68], respectively) and P.

146 *aeruginosa* (20.6% [7/34] and 17.6% [12/68], respectively).

147

148 Antibiotic susceptibility

Among K. pneumoniae isolates, non-susceptibility proportions were 77% (64/83) for third-

150 generation cephalosporins (3GC), 26% (12/47) for carbapenems, 60% (50/84) for

- 151 fluoroquinolones, and 50% (11/22) for cotrimoxazole (Figure 2, Table S3-4). Among P.
- aeruginosa isolates, non-susceptibility proportions were 24% (4/17) for carbapenems, 33%
- 153 (14/43) for fluoroquinolones, 27% (13/48) for amikacin and 42% (20/48) for gentamicin. Among
- *E. coli* isolates, non-susceptibility proportions were 33% (4/12) for carbapenems, 57% (16/28)
- 155 for fluoroquinolones, 65% (26/40) for 3GC, 51% (20/39) for gentamicin, 13% (5/39) for amikacin
- and 77% (10/13) for cotrimoxazole. Among Acinetobacter spp isolates, non-susceptibility
- 157 proportions was 57% (8/14) for carbapenems. Among *Enterobacter spp* isolates, non-
- susceptibility proportions were 81% (21/26) for ceftazidime, 60% (3/5) for carbapenems, 44%
- 159 (8/18) for fluoroquinolones, 43% (12/28) for amikacin, 57% (16/28) for gentamicin and 13% (1/8)
- 160 for cotrimoxazole. Among S. aureus isolates, non-susceptibility proportions were 71% (5/7) for
- 161 oxacillin and 0% (0/11) for vancomycin. Among *E. faecalis* isolates, non-susceptibility
- 162 proportions was 12% (2/17) for vancomycin and 60% (9/15) for ampicillin.
- 163

164 Multi-drug resistance was 30% (26/86) for K. pneumoniae, 29% (14/49) for P. aeruginosa, 49%

165 (20/41) for *E. coli*, 42% (15/36) for *Acinetobacter spp*, and 71% (5/7) for *S. aureus*.

166

167 Discussion

168

169 This "snapshot" study in Indonesian hospitals in 2019 suggested that AMR levels may be 170 among the highest reported in national AMR surveillance reports from Southeast Asia, and substantially higher than those reported from Europe.¹⁵ Resistance proportions were at alarming 171 levels for the WHO-defined high-priority bacteria-antibiotic combinations,¹³ i.e. 3GC-resistant *K*. 172 173 pneumoniae (77%) and E. coli (65%); carbapenem-resistant K. pneumoniae (26%), P. 174 aeruginosa (24%), E. coli (33%), Acinetobacter spp (57%), Enterobacter spp (60%); and 175 meticillin-resistant S. aureus (71%). Our findings are in line with the first Indonesian submission 176 from 20 tertiary sentinel hospitals to the pathogen-focused WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2020,¹⁵ which reported 79% 3GC-177 178 resistant K. pneumoniae, 40% meticillin-resistant S. aureus, 4% carbapenem-resistant E. coli, 179 65% fluoroquinolone-resistant E. coli and 51% carbapenem-resistant Acinetobacter spp in blood 180 specimens. For reference, between 2016-2020, K. pneumoniae resistance to 3GC and carbapenems was 32% and 5% in Malaysia, 53% and 27% in Vietnam, 54% and 21% in 181 Philippines and 31% and 8% in Europe respectively.¹⁶ *P. aeruginosa* resistance to 182 fluoroquinolones and carbapenems were 6% and 8% in Malaysia, 43% and 45% in Vietnam, 183 13% and 17% in Philippines and 19% and 17% in Europe respectively.^{17,18} S. aureus resistance 184 to meticillin was 18% in Malaysia, 51% in Philippines and 16% in Europe. 185 186 187 The study also demonstrated that the potential of bacterial cultures to target antibiotic therapy

188 was substantially underused. Notably, a blood culture was taken in just over half of the sepsis

patients, and a sputum culture in a quarter of pneumonia patients. Moreover, positive blood

culture results often reached the treating clinicians with delays, limiting clinical decision-making
 on de-escalating or stopping antibiotics. Culture underuse may be due to lack of laboratory
 capacity, cost-prohibitive bacterial culture testing and thresholds of national health insurance
 coverage, absence of clear culture guidelines, as well as long turnaround time and/or lack of
 trust in the results.¹⁹

195

196 The study has some limitations. First, the reliance on routinely collected culture specimens may 197 have caused overrepresentation of drug-resistant infections, given that a culture may have been preferentially performed on more severe, non-responding and antibiotic-treated patients.¹⁹ 198 199 Second, the use of routine data may have caused variations in, for instance, clinical diagnosis, 200 antibiotic indications, and quality and interpretation of culture results. Lastly, the limited hospital 201 sample precludes generalizing the findings to other hospitals or the country. More granular AMR 202 data are required to better estimate the extent of the problem, at the national and hospital 203 levels, across the spectrum from tertiary to peripheral facilities. 204 205 In conclusion, despite progress in implementing Indonesia's National Action Plan on AMR, there 206 is a great need for stronger, more granular AMR surveillance, coupled with inter-disciplinary

implementation research on stewardship interventions to inform local antibiotic guidelines and
 stewardship programs.

209 Acknowledgements

- 210 The authors are grateful to the management, research/medical committees and clinical staff of
- the participating hospitals for their support to the study.
- 212

213 EXPLAIN study group

- 214 Erni J. Nelwan, Ralalicia Limato, Manzilina Mudia, Monik Alamanda, Helio Guterres, Enty Enty,
- 215 Ifael Y. Mauleti, Maria Mayasari, Iman Firmansyah, May Hizrani, Anis Karuniawati, Prof Taralan
- 216 Tambunan, Prof Amin Soebandrio, Decy Subekti, Iqbal Elyazar, Mutia Rahardjani, Fitria
- 217 Wulandari, Prof Reinout van Crevel, H. Rogier van Doorn, Vu Thi Lan Huong, Nga Do Ti Thuy,
- 218 Sonia Lewycka, Prof Alex Broom, Raph L. Hamers.
- 219

220 Funding

- 221 This work and RLH And HRVD are supported by the Wellcome Africa Asia Programme Vietnam
- 222 (106680/Z/14/Z). RL is supported by an OUCRU Prize Studentship and a Nuffield Dept of
- 223 Medicine Tropical Network Fund DPhil Bursary.
- 224
- 225 Transparency declarations
- 226 None to declare
- 227

228 Author contributions

229 EJN and RLH conceived the idea for the study and are the principal investigators. RLH and RL

obtained the funding. RL, EJN, HVTL and RLH designed the study protocol and developed the

- study instrument. MM, ERM, IYM, MM, IF, and RD collected and verified the data, overseen by
- 232 RL. RL, MM, MA, JDB created and curated the database. JDB performed the analysis and had
- full access to all study data. JDB drafted the paper, with critical inputs from RLH. All authors
- critically revised the manuscript and gave approval for the final version to be published.

235

236 Data Availability Statement


- 237 De-identified data are available upon reasonable request via the corresponding author, after
- 238 written permission has been obtained from the lead investigators.

239 **References**

- Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in 2019:
 a systematic analysis. *Lancet* 2022.
- 242 2. Van Boeckel TP, Gandra S, Ashok A et al. Global antibiotic consumption 2000 to 2010:
- an analysis of national pharmaceutical sales data. *Lancet Infect Dis* 2014; **14**: 742-50.
- 3. Klein EY, Van Boeckel TP, Martinez EM et al. Global increase and geographic
- convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S A 2018;
- 246 **115**: E3463-E70.
- 4. Gandra S, Alvarez-Uria G, Turner P et al. Antimicrobial Resistance Surveillance in Low-
- and Middle-Income Countries: Progress and Challenges in Eight South Asian and Southeast
- Asian Countries. *Clin Microbiol Rev* 2020; **33**.
- 5. Chereau F, Opatowski L, Tourdjman M et al. Risk assessment for antibiotic resistance in
 South East Asia. *BMJ* 2017; **358**: j3393.
- Menteri Kesehatan Republik Indonesia. Program Pengendalian Resistensi Antimikroba
 Di Rumah Sakit. 2015.
- 254 7. The Center for Disease DEP. ResistanceMap: Antibiotic resistance.
- 255 <u>https://resistancemap.cddep.org/AntibioticUse.php</u> (September 28, 2021.
- 256 8. Zellweger RM, Carrique-Mas J, Limmathurotsakul D et al. A current perspective on
- antimicrobial resistance in Southeast Asia. *J Antimicrob Chemother* 2017; **72**: 2963-72.
- 258 9. Parathon H, Kuntaman K, Widiastoety TH et al. Progress towards antimicrobial
- resistance containment and control in Indonesia. *BMJ* 2017; **358**: j3808.
- 10. Lestari ES, Severin JA, Filius PM et al. Antimicrobial resistance among commensal
- 261 isolates of Escherichia coli and Staphylococcus aureus in the Indonesian population inside and
- outside hospitals. *Eur J Clin Microbiol Infect Dis* 2008; **27**: 45-51.


263	11.	Mendes RE, Mendoza M, Banga Singh KK et al. Regional resistance surveillance	
264	program results for 12 Asia-Pacific nations (2011). Antimicrob Agents Chemother 2013; 57:		
265	5721-6.		
266	12.	Limato R, Nelwan EJ, Mudia M et al. A multicentre point prevalence survey of patterns	
267	and quality of antibiotic prescribing in Indonesian hospitals. JAC Antimicrob Resist 2021; 3:		
268	dlab047.		
269	13.	Tacconelli E, Carrara E, Savoldi A et al. Discovery, research, and development of new	
270	antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect		
271	<i>Dis</i> 2018; 18 : 318-27.		
272	14.	Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-	
273	resistant and pandrug-resistant bacteria: an international expert proposal for interim standard		
274	definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.		
275	15.	World Health Organization. Global antimicrobial resistance and use surveillance systems	
276	Country Profiles. https://www.who.int/data/gho/data/themes/topics/global-antimicrobial-		
277	resistance-surveillance-system-glass/glass-country-profiles (October 19, 2021.		
278	16.	Vu TVD, Choisy M, Do TTN et al. Antimicrobial susceptibility testing results from 13	
279	hospitals in Viet Nam: VINARES 2016-2017. Antimicrob Resist Infect Control 2021; 10: 78.		
280	17.	Antibiotic Resistance Surveillance Reference Laboratory KL, Malaysia,. National	
281	Antibiotic Resistance Surveillance Report 2019. 2019.		
282	18.	Manila: Antimicrobial Resistance Surveillance Program. Antimicrobial Resistance	
283	Surveilance Program Annual Report - 2020. 2021.		
284	19.	Lim C, Ashley EA, Hamers RL et al. Surveillance strategies using routine microbiology	
285	for ant	timicrobial resistance in low- and middle-income countries. Clin Microbiol Infect 2021; 27:	
286	1391-9	9.	

Figure 1: Etiology of community-acquired and hospital-acquired infections.



The category 'Other' comprised coagulase-negative staphylococci (12%, n=33), *Serratia marcescens* (2%, n=5), *Klebsiella oxytoca,* viridans group streptococci (each 1%, n=3), *Proteus mirabilis, Vibrio vulnicus, Moraxella catarrhalis* (each 1%, n=2), and *Stenotrophomonas maltophilia, Citrobacter freundii, Streptococcus mitis, Pseudomonas putida, Enterococcus avium, Morganella morganii* and *Proteus vulgaris* (each <1%).

Figure 2: Proportion of non-susceptibility among common Gram-negative and Gram-positive isolates.



Abbreviations: AMK = amikacin, AMP = ampicillin, CAZ = ceftazidime, CIP = ciprofloxacin, CLI = clindamycin, CRO = ceftriaxone, CTX = cefotaxime, DOR = doripenem, ERY = erythromycin, GEN = gentamicin, IPM = imipenem, LVX = levofloxacin, LZD = linezolid, MEM = meropenem, OXA = oxacillin, SXT = trimethoprim-sulphamethoxazole, TGC = tigecycline, TZP = piperacillin/tazobactam, VAN = vancomycin.